Title: Systemic Lupus Erythematosus Market - Growing Opportunities
1Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
InnovationbyGBI Research
- Explore all reports for Autoimmune Drugs
market - _at_
- http//www.rnrmarketresearch.com/reports/life-scie
nces/pharmaceuticals/diseases-treatment/autoimmune
-drugs .
2Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation
- The Systemic Lupus Erythematosus (SLE) drug
market is currently under-served by non-generic,
targeted therapies. Whilst the only Food and Drug
Administration (FDA)-approved biologic, Benlysta
(belimumab), generated sales of 111m in 2012,
there is little evidence that the drugs
performance is significantly superior to other
B-cell targeted therapies such as Rituxan
(rituximab), which is often used off-license to
treat refractory SLE patients. Therapeutics
entering the market therefore do not face the
staggering level of competition from currently
marketed programs as in other markets such as the
Rheumatoid Arthritis (RA) market. Emerging market
entrants that appear to offer significant
therapeutic benefits are likely to cause dramatic
changes to the market landscape. - A growing understanding of the signaling pathways
underlying SLE pathophysiology including, but not
limited to, B cells, T cells and intracellular
kinases, is translating into a higher number of
novel, and more importantly, first-in-class
targeted therapeutics entering the developmental
pipeline. In particular, a high level of
investment in the development of
cytokine-blocking strategies is evident, as
therapies targeting the interferon pathway are
relatively common in the pipeline. - Inquire for Discount _at_
- http//www.rnrmarketresearch.com/contacts/discount
?rname145685 .
3Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation
- Scope
- The report analyzes the market for SLE
therapeutics and the pipeline products in that
market, with particular emphasis on
first-in-class programs. - A brief introduction to SLE, including symptoms,
pathophysiology, disease scoring indices and
overview of pharmacotherapy - In-depth analysis and literature review on
marketed products, including analyses of their
safety, efficacy, treatment patterns and
strengths/weaknesses, based on published clinical
trials, as well as a reference table of drugs in
terms of safety and efficacy - Overview of how innovation products are
contributing to the market for SLE therapeutics - Comprehensive review of the pipeline for
first-in-class therapies, which is analyzed on
the basis of phase distribution, molecule types
and molecular targets, as well as administration
routes - The changing molecular target landscape between
market and pipeline, and, in particular, focal
points of innovation - First-in-class molecular targets, highlighting
early-stage programs for which clinical utility
has yet to be evaluated, as well as an in-depth
literature review on novel molecular targets - Complete Report Available _at_
- http//www.rnrmarketresearch.com/frontier-pharma-s
ystemic-lupus-erythematosus-identifying-and-commer
cializing-first-in-class-innovation-market-report.
html .
4Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation
- Reasons to buy
- The report will assist the business development
strategies of companies that wish to develop
novel therapies with improved benefits to
existing treatments. It will also be of interest
to companies seeking to expand their pipeline
portfolio through licensing agreements and
co-development deals. Primarily, the report will
allow clients to identify and understand market
opportunities and the emerging competitive
environment. It will also allow you to - - Understand the SLE pipeline and the factors which
indicate that it is becoming more innovative - Understand the overall focal shifts in
therapeutic molecular targets for the treatment
of SLE - Understand the distribution of the pipeline
programs by phase of development, molecule type
and molecular target - Identify the list of first-in-class programs that
are potentially open to deal-making opportunities - Understand the first-in-class developmental
programs and gauge the current clinical
effectiveness based on animal models - Buy a copy of report _at_
- http//www.rnrmarketresearch.com/contacts/purchase
?rname145685 .
5Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation
- Table of Contents
- 1 Table of Contents 41.1 List of Tables 51.2
List of Figures 6 - 2 Introduction 72.1 The Case for Innovation in
Systemic Lupus Erythematosus 72.2 Growing
Opportunities for Biologic Products 72.3
Diversification of Molecular Targets 72.4
Innovative First-in-Class Product Developments
Remain Attractive 82.5 Changes in the Clinical
and Commercial Environment to be More Favorable
to Products Targeting Niche Patient Populations
and Indications 82.6 Sustained Innovation 8 - 3 Systemic Lupus Erythematosus 93.1 Disease
Overview 93.2 Epidemiology 9 - Request Sample copy of this report _at_
http//www.rnrmarketresearch.com/contacts/request-
sample?rname145685 .
6Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation
- For more details contact Mr. Priyank Tiwari
sales_at_rnrmarketresearch.com / 18883915441
RnR Market Research RnRMarketResearch.com, an
online repository of market research reports,
offers in-depth analysis of over 5000 market
segments. RnR Market Research library has
syndicated reports by leading market research
publishers across the globe.